2019 STUDY: long term efficacy of 10 year finasteride usage

[FBl]

"We evaluated the long-term (10-year) efficacy and safety of AGA treatment with 1 mg/day finasteride in a large study population (532 patients), as the first study of this kind in Japan, to our knowledge." A high objective efficacy was demonstrated by the MGPA, which revealed improvement and prevention of disease progression in 99.1% of the 532 Japanese men with AGA treated with 1 mg/day finasteride for 10 years. Furthermore, the outcome was similar to or better than that reported by other studies in Japan [8-10,13,17]. Differences have been known to occur in the progression of AGA symptoms between Japanese and Caucasian men [8,18]. This efficacy of the investigated treatment in Japanese men exceeded that reported in other studies in Caucasians. The superior response of Japanese men with AGA was reported to likely be attributable to their hair characteristics (greater diameter, black color, and lower density), which facilitated the detection of slight changes [10,19-23]. A novel finding observed in this study was the significant difference in the improvement of AGA following finasteride treatment between the N-H: I/II/III and N-H: IV/V/VI/VII groups at the first visit. The ROC analysis revealed a similar difference, that was performed to classify patients with improvement (MGPA≥5) and deteriorating (MGPA<5) condition at year 10 of treatment; the cut-off point was N-H: III (AUC: 0.746). Furthermore, the MGPA of the total study population and the N-H: I/II/III group at the first visit significantly improved from treatment year 5 to 10 (P<0.001). This efficacy was different from that of a 5-year study in Japanese men, which reported that the efficacy began to plateau after 4 years of treatment [10]. Several studies have reported that AGA progresses in N-H classification with age, [7,11,12,18] and that younger patients show more improvement than that of older patients with AGA treatment [24,25]. In this study, AGA patients at the early stage of N-H classification showed more improvement than patients at the later stage did.

Results
Patient Characteristics:- The characteristics of all patients evaluated for AGA treatment efficacy were as follows: age at first visit, 37.8 ± 10.0 years; age range, 20–69 years; and values of each N-H at the first visit: I/II/III/IV/V/VI/VII, 6/116/204/124/61/18/3, respectively.
Efficacy Evaluation in 10 years treatment
Objective efficacy - Scalp photographs
The proportions of patients with improvement (MGPA ≥ 5) or prevention of disease progression (MGPA ≥ 4) at treatment year 10 were 91.5% (487/532) and 99.1% (527/532), respectively. The efficacy evaluation showed that the MGPA improved significantly from year 1 through to year 10 of treatment compared with the baseline (MGPA = 4). The MGPA of each N-H group was linear according to the N-H number; the total was between N-H:III and N-H:IV (Figure 4 and Table 1). Receiver operating characteristic curve (ROC) analysis was performed to classify patients with improvement (MGPA ≥ 5) and deteriorating (MGPA<5) condition at year 10 of treatment; the cut-off point was N-H: III. (the area under the curve [AUC], which indicates the predictive value, was 0.746.). Furthermore, the MGPA of the total study population and the N-H:I/II/III group at the first visit improved from year 5 through to year 10, with statistically significant differences (P<0.001). The early stage AGA group (N-H: I/II/III at first visit) showed more improvement with long-term AGA treatment (10-year) with finasteride than the other groups did in the objective evaluation. The N-H classification of AGA patients improved by approximately 1 grade over the 10-year treatment with finasteride; significant differences were observed from pre-treatment (3.35 ± 1.11) to post-treatment (2.55 ± 1.30, P<0.001) in comparison of digitized classification.

(Figure 4. Changes in modified global photographic assessment scores (MGPA) from before treatment through year 10 of treatment on each Norwood-Hamilton scale (N-H) group at first visit.)

Safety Evaluation

During the study period for 10 years, no serious adverse reaction was recognized. Mild and temporary adverse reactions were recorded in 6.8% (36⁄532) of the entire study population by questionnaire. The adverse reactions were decreased libido (5.6%, n=30) and erectile dysfunction (3.0%, n=16). All adverse reactions were mild and all patients continued treatment for 10 years.

Long-term (10-year) efficacy of finasteride in 523 Japanese men with androgenetic alopecia

OA Text is an independent open-access scientific publisher showcases innovative research and ideas aimed at improving health by linking research and practice to the benefit of society.

www.oatext.com

 

[Sens]

 

[FBl]

View attachment 2527797

sideeffects:

- more hair
- less cortisol (no worrying about hairline recession)
- more dopamine (no worrying about hairline recession)
- better sleep (no worrying about hairline recession)
- cure of depression (no worrying about hairline recession)
- more sex (baldcels dont even need a penis so why do they worry about finasterid killing their dick?)

 

[Deleted member 47332]

Approach the cause the not the symptom.

Whenever you have hair loss it occurs usually with people who have a lot of testosterone. . Even in women who have a lot of testosterone. Cholesterol which the foundation for the production of many hormones is responsible for binding with toxins. What happens is the body uses the testosterone to detoxify, so it will grab mercury out of the brain, thallium, lead – anything that’s in the brain - and , those are more concentrated in the nervous system and brain because the brain uses metallic metals to conduct electricity and transfer light. So, metallic minerals are the strongest in concentration in the brain and nervous system. So when the brain throws it off, it throws it out through the scalp – damages the follicles, so all you can do is try to protect it. Men and women who are high in testosterone can detoxify more at one time because of the high rate of fat and protein in the testosterone molecules.

Putting raw butter or raw bone marrow on the scalp will help protect those follicles and help re-grow sometimes.

 

[Maalik]

Approach the cause the not the symptom.

Whenever you have hair loss it occurs usually with people who have a lot of testosterone. . Even in women who have a lot of testosterone. Cholesterol which the foundation for the production of many hormones is responsible for binding with toxins. What happens is the body uses the testosterone to detoxify, so it will grab mercury out of the brain, thallium, lead – anything that’s in the brain - and , those are more concentrated in the nervous system and brain because the brain uses metallic metals to conduct electricity and transfer light. So, metallic minerals are the strongest in concentration in the brain and nervous system. So when the brain throws it off, it throws it out through the scalp – damages the follicles, so all you can do is try to protect it. Men and women who are high in testosterone can detoxify more at one time because of the high rate of fat and protein in the testosterone molecules.

Putting raw butter or raw bone marrow on the scalp will help protect those follicles and help re-grow sometimes.

username checks out

 

[12PSLsubhuman]

View attachment 2527797

All that for waiting until NW3 and trying to use obscure chemicals cooked up in the streets of beijing

 

[reptiles]

Results
Patient Characteristics:- The characteristics of all patients evaluated for AGA treatment efficacy were as follows: age at first visit, 37.8 ± 10.0 years; age range, 20–69 years; and values of each N-H at the first visit: I/II/III/IV/V/VI/VII, 6/116/204/124/61/18/3, respectively.
Efficacy Evaluation in 10 years treatment
Objective efficacy - Scalp photographs
The proportions of patients with improvement (MGPA ≥ 5) or prevention of disease progression (MGPA ≥ 4) at treatment year 10 were 91.5% (487/532) and 99.1% (527/532), respectively. The efficacy evaluation showed that the MGPA improved significantly from year 1 through to year 10 of treatment compared with the baseline (MGPA = 4). The MGPA of each N-H group was linear according to the N-H number; the total was between N-H:III and N-H:IV (Figure 4 and Table 1). Receiver operating characteristic curve (ROC) analysis was performed to classify patients with improvement (MGPA ≥ 5) and deteriorating (MGPA<5) condition at year 10 of treatment; the cut-off point was N-H: III. (the area under the curve [AUC], which indicates the predictive value, was 0.746.). Furthermore, the MGPA of the total study population and the N-H:I/II/III group at the first visit improved from year 5 through to year 10, with statistically significant differences (P<0.001). The early stage AGA group (N-H: I/II/III at first visit) showed more improvement with long-term AGA treatment (10-year) with finasteride than the other groups did in the objective evaluation. The N-H classification of AGA patients improved by approximately 1 grade over the 10-year treatment with finasteride; significant differences were observed from pre-treatment (3.35 ± 1.11) to post-treatment (2.55 ± 1.30, P<0.001) in comparison of digitized classification.
View attachment 2527792

Safety Evaluation

During the study period for 10 years, no serious adverse reaction was recognized. Mild and temporary adverse reactions were recorded in 6.8% (36⁄532) of the entire study population by questionnaire. The adverse reactions were decreased libido (5.6%, n=30) and erectile dysfunction (3.0%, n=16). All adverse reactions were mild and all patients continued treatment for 10 years.

Long-term (10-year) efficacy of finasteride in 523 Japanese men with androgenetic alopecia

OA Text is an independent open-access scientific publisher showcases innovative research and ideas aimed at improving health by linking research and practice to the benefit of society.

www.oatext.com

Here are the key findings from this study on the long-term (10-year) efficacy and safety of finasteride treatment for androgenetic alopecia (AGA) in Japanese men:

High efficacy was seen with 99.1% of patients (527/532) showing improvement or prevention of AGA progression after 10 years of 1mg/day finasteride treatment.
91.5% of patients (487/532) had improvement in AGA based on the modified global photographic assessment (MGPA score ≥5).
The mean MGPA score significantly improved from 4 at baseline to 6.45 after 10 years of treatment (p<0.001).
Patients with early stage AGA (Norwood-Hamilton I-III) showed greater improvement in MGPA score over 10 years compared to those with more advanced AGA (Norwood-Hamilton IV-VII).
ROC analysis showed the cut-off for improvement at 10 years was Norwood-Hamilton stage III (AUC 0.746).
MGPA continued to improve from year 5 to 10 in early stage AGA patients (p<0.001), suggesting ongoing benefits with long-term treatment.
Adverse effects were mild and temporary, seen in 6.8% of patients. No serious adverse events were reported.
In summary, this large 10-year study demonstrates high efficacy and safety of long-term 1mg/day finasteride treatment for AGA in Japanese men, especially those with early stage disease. The data analysis provides robust evidence supporting the benefits of sustained finasteride use for preventing progression and improving AGA

 

[reptiles]

Results
Patient Characteristics:- The characteristics of all patients evaluated for AGA treatment efficacy were as follows: age at first visit, 37.8 ± 10.0 years; age range, 20–69 years; and values of each N-H at the first visit: I/II/III/IV/V/VI/VII, 6/116/204/124/61/18/3, respectively.
Efficacy Evaluation in 10 years treatment
Objective efficacy - Scalp photographs
The proportions of patients with improvement (MGPA ≥ 5) or prevention of disease progression (MGPA ≥ 4) at treatment year 10 were 91.5% (487/532) and 99.1% (527/532), respectively. The efficacy evaluation showed that the MGPA improved significantly from year 1 through to year 10 of treatment compared with the baseline (MGPA = 4). The MGPA of each N-H group was linear according to the N-H number; the total was between N-H:III and N-H:IV (Figure 4 and Table 1). Receiver operating characteristic curve (ROC) analysis was performed to classify patients with improvement (MGPA ≥ 5) and deteriorating (MGPA<5) condition at year 10 of treatment; the cut-off point was N-H: III. (the area under the curve [AUC], which indicates the predictive value, was 0.746.). Furthermore, the MGPA of the total study population and the N-H:I/II/III group at the first visit improved from year 5 through to year 10, with statistically significant differences (P<0.001). The early stage AGA group (N-H: I/II/III at first visit) showed more improvement with long-term AGA treatment (10-year) with finasteride than the other groups did in the objective evaluation. The N-H classification of AGA patients improved by approximately 1 grade over the 10-year treatment with finasteride; significant differences were observed from pre-treatment (3.35 ± 1.11) to post-treatment (2.55 ± 1.30, P<0.001) in comparison of digitized classification.
View attachment 2527792

Safety Evaluation

During the study period for 10 years, no serious adverse reaction was recognized. Mild and temporary adverse reactions were recorded in 6.8% (36⁄532) of the entire study population by questionnaire. The adverse reactions were decreased libido (5.6%, n=30) and erectile dysfunction (3.0%, n=16). All adverse reactions were mild and all patients continued treatment for 10 years.

Long-term (10-year) efficacy of finasteride in 523 Japanese men with androgenetic alopecia

OA Text is an independent open-access scientific publisher showcases innovative research and ideas aimed at improving health by linking research and practice to the benefit of society.

www.oatext.com

Let me break down the study at well mgpa Modified Global Photographic Assessment. Refers to a 1 to 7 scale that measures hair loss 1 is bad hair loss 7 is no hair loss.

The patient's experienced an mgpa of 4 to 6.5 over 10 years which means the hair loss was almost 0.

The p value 0.001 represents the likelihood hood of this being simple by chance hence it shows correlation wise it is heavily good for those experiencing hair loss.


The Norwood Hamilton score represents the severity of hair loss.

An roc analysis represents an ability to diffentiate the 2 effects the X axis represents relates those who were predicted to improve the y represents those who failed to improve and the lines on the graph represents the improvement or worsening of the scale over the years

 

[Hortensia]

been using finasteride for two years now, have yet to experience any side effects.